

WP4R NEWSLETTER

2023

May 2023



WHO WE ARE

We are a center created to provide information on clinical trials so patients can fully consider their opportunities to get involved in research.



WHAT WE DO

We provide research information to the community and serve researchers by helping to increase participation in studies.



WHY IT MATTERS

We support increased clinical trial participation to accelerate discoveries to improve health.

Key Highlights

Community Research Summary

GHUCCTS in the Virtual Community

- Safely Moving Women's Health Forward
- Sickle Cell
- Breast Cancer Awareness

Actively Enrolling Studies


Connect With Us!

We **PARTNER**
for **RESEARCH**

Georgetown University | Howard University
MedStar Health Research Institute | DC Veterans Affairs Medical Center
Oak Ridge National Laboratory

COMMUNITY RESEARCH SUMMARIES

The objective of the **GHUCCTS Community Summaries** is to ensure study updates and results are communicated to the study participants and the general community. Study findings can help improve health and medicine.



CSSC-004 CONVALESCENT PLASMA FOR TREATMENT

• What was the research about?

This research was focused on treatment for outpatients who were infected* with COVID-19, and it took place before recent FDA approved therapies. Researchers were trying to determine if antibodies* from people who recovered from infection could treat infection and prevent hospitalization in people who were recently infected, but who were not yet hospitalized.


1181 infected research volunteers received “Convalescent Plasma” *, which is a blood component that contains antibodies from people who recovered from infection, or they received placebo* (plasma without antibodies). The plasma used in this study was “high titer”, which indicates the presence of high levels of antibodies in the blood samples. (See figure)

• Why was this research conducted?

Researchers were interested in preventing severe complications in people recently infected* with COVID-19. There were limited proven and FDA-approved treatment options at the time, and they were only for patients who were hospitalized with severe COVID-19. The approach used in this study is known as “passive immunotherapy” – it has been used to treat many other infections and chronic diseases, and it has been shown to be very safe.

• What was learned?

Researchers concluded that hospital admissions were reduced by *more than 50%* in patients who received high-titer convalescent plasma. There were 1181 participants who were given plasma samples, 592 received the high-titer convalescent plasma, while 589 received control plasma (which is placebo and did not contain any antibodies). Those experiencing symptoms* within eight days of infection were enrolled in this study. After 28 days of study, only 3% of people who received the high-titer plasma were hospitalized, while 6% of those who received placebo were.



Shown is the process of obtaining and transferring convalescent plasma between individuals. A donor sample is blood matched to the individual who then receives the infusion.

GITVC

FOLLOW OUR YOUTUBE CHANNEL OR CLICK BELOW TO LISTEN TO OUR EDUCATIONAL WEBINAR SERIES DELIVERED BY OUR INVESTIGATORS



Safely Moving Women's Health Forward...

Learning from History: Safely Moving Women's Health Forward

This clip is from our April 27, 2021 GITVC webinar.

GHUCCTS in the Virtual Community (GITVC)

Guest Speaker: Veronica Thomas, PhD
Professor, Human Development & Psychology, Catholic University of America

Guest Speaker: Tatiana Santos, MD
Associate Professor, Obstetrics & Gynecology, Howard University College of Medicine

"SAFELY MOVING WOMEN'S HEALTH FORWARD"

April 2021

+ Don't Let the Past Hold Back the Future of Health

Click Here!

"SICKLE CELL AWARENESS"

Sep 2021

+ How Are Participants Protected in Research?

Click Here!



Sickle Cell Awareness, Sickle Cell Tr...

Guest Speaker: James Taylor VI, MD

James Taylor VI, MD is the director of the Center for Sickle Cell Disease at Howard University. He is a Professor and Attending Hematology/Oncology, and he was at the NIH. He is committed to NIH's research programs with a focus on new treatments and curative therapy for sickle cell disease. Dr. Taylor earned his MD in 1995, then trained in St. Louis, NIH and John's Hopkins.

Watch on  YouTube



GHUCCTS Breast Cancer Screening, Quality...

Guest Speaker: Alejandra Hurtado de Mendoza, PhD

Dr. Mendoza is an Assistant Professor at the Cancer Prevention and Control Program at Georgetown Lombardi Comprehensive Cancer Center. She is a bilingual Social Psychologist with training in Anthropology and Culture, and Technology. She uses interdisciplinary approaches in psychology, behavioral science, and communication to develop and evaluate interventions that address stark disparities in the uptake of genetic risk assessment in high-risk underserved groups. Her research focuses on translational genomics with underserved populations.

Watch on  YouTube

Georgetown University | Howard University
MedStar Health Research Institute | Oak Ridge National Laboratory | Washington DC Veterans Affairs Medical Center

"BREAST CANCER AWARENESS"

Oct 2021

+ Henrietta Lacks Changed History in More Ways than One

Click Here!

May 2023



ARE YOU INTERESTED IN PARTICIPATING IN A RESEARCH STUDY?

THE FOLLOWING STUDIES ARE SEEKING PARTICIPANTS!



Study of Treatment and Reproductive Outcomes

MWCCS (HIV Study)

Collaborative research effort that aims to understand and reduce the impact of chronic health conditions—including heart, lung, blood, and sleep (HLBS) disorders—that affect people living with HIV.

STAR (HIV Study)

Seeks to answer questions related to the effects of HIV infection and HIV-related medical conditions on women of reproductive age.



NIH/Georgetown University HIV Studies

MWCCS

Help understand HIV infection!

- WE ARE LOOKING FOR:**
- ◆ HIV POSITIVE women 30-70 years old
 - ◆ HIV NEGATIVE women 30-70 years old

MWCCS is a long-term study involving a physical exam, lab work and an interview annually.

You will be compensated for your time!

For more information contact:
DC: 202-784-2687
VA: 703-321-2674
mwccsstudy@georgetown.edu

STAR

Help understand HIV infection in young women!

- WE ARE LOOKING FOR:**
- ◆ HIV POSITIVE women 18-45 years old
 - ◆ HIV NEGATIVE women 18-45 years old

STAR is a long-term study involving a physical exam, lab work and an interview annually.

You will be compensated for your time!

For more information contact:
DC: (202) 384-7815
VA: 703-321-2674
starstudy@georgetown.edu

IS YOUR MEMORY NOT WHAT IT USED TO BE?

Memory loss associated with aging can be mild cognitive impairment (MCI), a precursor to Alzheimer's disease.

The MIND Study is testing whether the safe and innovative use of nicotine, delivered through a patch, can improve memory and functioning in people who have been diagnosed with MCI.

If you are a healthy, non-smoking adult over the age of 55, please visit [MINDStudy.org](https://www.MINDStudy.org) or call **1-866-MIND-150** (1-866-646-3150) to learn more.

Funded by the National Institutes of Health and the Alzheimer's Drug Discovery Foundation.



Thank You!

Keep in Touch
&

Follow Us On Our Platforms Below!



@GHUCCTSCommunity

<https://www.facebook.com/GHUCCTSCommunity>



@ghuccts_community

https://www.instagram.com/ghuccts_community/



@ghucctsadministration146

<https://www.youtube.com/@ghucctsadministration146>

GHUUCTS Main Page:

<http://www.georgetownhowardctsa.org>

We **PARTNER**
for **RESEARCH**

Georgetown University | Howard University
MedStar Health Research Institute | DC Veterans Affairs Medical Center
Oak Ridge National Laboratory

<https://www.wepartner4research.org/>